Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The first group of participants recruited into the CL4P-CF trial is helping to test the effect of using an automated insulin delivery system in people with cystic fibrosis-related diabetes.

Image of a closed loop insulin delivery system for diabetes © Ypsomed

Addenbrooke’s Hospital and the Royal Papworth Hospital in Cambridge have started recruiting adults with cystic fibrosis-related diabetes to the CL4P-CF trial. The trial is investigating whether an automated insulin delivery system –CamAPS® FX – improves glucose control (as measured by glucose ‘time in range’) compared with standard insulin therapy plus a glucose sensor. This system is known by some as a ‘hybrid closed-loop system’ or an ‘artificial pancreas’.  

Other study sites opening soon include Wythenshawe Hospital in Manchester, Oxford University Hospitals and the Royal Brompton Hospital in London.

We would like to thank the study participants and the Cystic Fibrosis Trust for their support; the trial is funded by the National Institute for Health and Care Research.

Read more about this trial for people living with cystic fibrosis-related diabetes.